Are there serious or life-threatening adverse reactions linked to memoblast?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
There are two distinct products in the available reporting that resemble the name “memoblast”: Ryoncil (Mesoblast’s mesenchymal stromal cell product) which has documented serious adverse events including hypersensitivity, infections and hemorrhage [1] [2], and commercial supplements called “Memo Blast”/“MemoBlast” that manufacturers claim have no significant side effects but provide only marketing statements, not independent safety data [3] [4] [5] [6]. Available sources do not mention a single product spelled “memoblast” with independent, peer‑reviewed safety data beyond these company sites and press summaries [1] [2] [3].
1. Two different things with similar names — a source of confusion
The reporting shows Mesoblast’s regulated cell therapy Ryoncil (also described as a mesenchymal stromal cell product and sometimes referred to in company materials) and a line of over‑the‑counter cognitive supplements called “Memo Blast” or “MemoBlast.” The cell therapy is discussed on Mesoblast and Ryoncil pages with FDA context [1] [7] [8], while the supplements appear on multiple commercial sites asserting safety and few side effects [3] [4] [5]. The similarity of names invites conflation; sources treat them as wholly separate products [1] [3].
2. Ryoncil (Mesoblast) — documented serious and life‑threatening reactions
Mesoblast’s Ryoncil information, and FDA‑focused reporting, lists hypersensitivity and acute infusion reactions as documented risks, including serious hypersensitivity and anaphylaxis tied to DMSO and trace animal proteins; guidance is to interrupt infusion and not re‑administer after life‑threatening reactions [1]. Trade reporting summarizing FDA approval also lists infections, hemorrhage, fever and abdominal pain among the most common adverse events seen in trials [2]. Company and investor materials instruct reporting side effects to Mesoblast or FDA and point readers to full prescribing information for additional Important Safety Information [1] [8].
3. MemoBlast supplements — company claims versus independent evidence
Manufacturer websites for MemoBlast and affiliates repeatedly claim “no significant side effects” and cite customer counts and ingredient safety as their basis [3] [4] [5]. At the same time, a third‑party retailer page notes possible minor effects such as digestive discomfort or allergic reactions to ingredients [6]. These are marketing and retail statements; none of the supplied sources cite independent clinical trials, regulatory safety reviews or adverse‑event databases for MemoBlast [3] [6]. Available sources do not mention independent, peer‑reviewed safety data for the supplement [3] [4].
4. What counts as “serious” or “life‑threatening” in the reporting
For Ryoncil, the reporting explicitly names serious, life‑threatening events: anaphylaxis and serious infusion reactions, and systemic complications recorded in trials such as infections and hemorrhage [1] [2]. For the MemoBlast supplement, company claims deny significant side effects and a retailer notes only minor and allergic reactions; no source reports life‑threatening events for the supplement [3] [6]. Therefore, the available evidence supports that the regulated Mesoblast product has documented serious risks, whereas the marketed supplement lacks independent reports of such severe adverse outcomes in these sources [1] [2] [3].
5. Implications for patients, caregivers and consumers
Patients considering a regulated cell therapy should treat the product as a prescription biologic with documented serious adverse events and follow FDA‑label guidance, including reporting mechanisms and contraindications after severe reactions [1] [8]. Consumers of over‑the‑counter MemoBlast should note that safety assertions come from sellers and not from independent regulatory findings in the provided material; possible allergic or digestive reactions are acknowledged in retail copy [3] [6]. Available sources do not mention interactions between either product and other medications or long‑term safety beyond trial summaries and marketing text [2] [3].
6. Limitations, open questions and where to look next
This summary relies solely on company sites, investor materials and trade coverage in the provided set; it does not include independent journal articles, regulatory databases or large pharmacovigilance datasets. For definitive safety profiles, consult the FDA prescribing information and adverse‑event reporting summaries for Ryoncil and seek peer‑reviewed clinical trial publications or regulatory reviews; for supplements, look for independent clinical trials and safety assessments [1] [2] [3]. Available sources do not mention a product exactly named “memoblast” with comprehensive independent safety reporting beyond the items cited here [1] [3].